The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Verena Hoffmann(Zimmer Biomet (Germany)), Rüdiger Hehlmann, Richard E. Clark(University of Liverpool), Andrija Bogdanović(University of Belgrade), Zuzana Sninská(University Hospital Bratislava), Tomasz Sacha, Fausto Castagnetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Perttu Koskenvesa(Helsinki University Hospital), Francesco Di Raimondo(Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele), Paul Costeas, G. Schubert-Fritschle(Ludwig-Maximilians-Universität München), Noortje Thielen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Michele Baccarani(University of Bologna), Hele Everaus(Tartu University Hospital), Jiřı́ Mayer(University Hospital Brno), Sandra Lejniece(Riga East University Hospital), A. Covelli(Novartis (Italy)), Andrey Zaritskey, Andrzej Hellmann(Gdańsk Medical University), Karel Indrák(Palacký University Olomouc), Gian Cesare Guidi(Novartis (Italy)), Laimonas Griškevičius(Vilnius University), Dubravka Sertić(University Hospital Centre Zagreb), Joerg Hasford(German Medical Association), Doris Lindoerfer(Zimmer Biomet (Germany)), Steegmann Jl(Hospital Universitario de La Princesa), Joëlle Guilhot(Inserm), Irena Zupan(Ljubljana University Medical Centre), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Bengt Simonsson(Uppsala University Hospital), Anna Turkina
Cited by 255
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573